Merck's pneumococcal shot shows promise in children and teens in study
Merck's pneumococcal vaccine showed strong immune responses in children and teens at higher risk of serious illness in a late-stage study, the drugmaker said.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.